The therapeutic landscape in haemophilia is evolving with new extended half-life factor concentrates now licenced in Europe and more to be licenced in 2017 and 2018. In addition, enrolment in Ireland for the clinical trials with the new by-passing agents such as Emicizumab and Fitusiran continue and screening for Gene Therapy clinical trials will commence in Ireland this year. These new products promise greater efficacy and more therapeutic options with novel methods of delivery. However, we will not lose sight of safety issues. Safety of haemophilia treatment is and will always continue to be a high priority for the Society. Through our website, our publications and our conferences, we will strive to keep you updated on any relevant safety issue in addition to updating you on the exciting developments coming down the line.